340 related articles for article (PubMed ID: 25261573)
1. Psoriatic arthritis treatment and the risk of herpes zoster.
Zisman D; Bitterman H; Shalom G; Feldhamer I; Comanesther D; Batat E; Greenberg-Dotan S; Cohen S; Cohen AD
Ann Rheum Dis; 2016 Jan; 75(1):131-5. PubMed ID: 25261573
[TBL] [Abstract][Full Text] [Related]
2. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
3. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
Liao TL; Chen YM; Liu HJ; Chen DY
BMJ Open; 2017 Jan; 7(1):e014032. PubMed ID: 28057661
[TBL] [Abstract][Full Text] [Related]
4. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
[TBL] [Abstract][Full Text] [Related]
6. Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.
Desai RJ; Solomon DH; Schneeweiss S; Danaei G; Liao KP; Kim SC
Epidemiology; 2016 May; 27(3):414-22. PubMed ID: 26808597
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.
Lin KM; Cheng TT; Lin JC; Chen CJ
Clin Rheumatol; 2015 Jun; 34(6):1039-46. PubMed ID: 25939523
[TBL] [Abstract][Full Text] [Related]
8. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
9. Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France.
Soubrier M; Pereira B; Frayssac T; Abdi D; Couderc M; Daron C; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Clin Exp Rheumatol; 2016; 34(6):1059-1064. PubMed ID: 27607233
[TBL] [Abstract][Full Text] [Related]
10. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study.
Aaltonen K; Heinonen A; Joensuu J; Parmanne P; Karjalainen A; Varjolahti-Lehtinen T; Uutela T; Puurtinen-Vilkki M; Arstila L; Blom M; Sokka T; Nordström D
Semin Arthritis Rheum; 2017 Jun; 46(6):732-739. PubMed ID: 28010883
[TBL] [Abstract][Full Text] [Related]
12. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
Winthrop KL; Baddley JW; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
JAMA; 2013 Mar; 309(9):887-95. PubMed ID: 23462785
[TBL] [Abstract][Full Text] [Related]
13. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
14. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.
Højgaard P; Glintborg B; Hetland ML; Hansen TH; Lage-Hansen PR; Petersen MH; Holland-Fischer M; Nilsson C; Loft AG; Andersen BN; Adelsten T; Jensen J; Omerovic E; Christensen R; Tarp U; Østgård R; Dreyer L
Ann Rheum Dis; 2015 Dec; 74(12):2130-6. PubMed ID: 25063827
[TBL] [Abstract][Full Text] [Related]
15. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
Nimmrich S; Horneff G
Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050
[TBL] [Abstract][Full Text] [Related]
16. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
[TBL] [Abstract][Full Text] [Related]
17. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
18. Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings.
Iannone F; Lopriore S; Bucci R; Lopalco G; Chialà A; Cantarini L; Lapadula G
J Rheumatol; 2016 May; 43(5):911-7. PubMed ID: 26980583
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis.
Mori Y; Kuwahara Y; Chiba S; Itoi E
Mod Rheumatol; 2015 May; 25(3):431-4. PubMed ID: 25295919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]